Alverno Laboratories continues to be an industry leader in developing rapid response to COVID-19 testing. “We are building an arsenal of capabilities to continue our battle with this terrible disease that has affected so many lives in so many ways,” Alverno CEO Sam...
“We are excited to be able to do our part in relieving some of the pressure on the national testing pipeline for COVID-19,” Terese added. “We understood early that providers such as LabCorp would quickly be flooded with specimens and that turnaround times would...
Alverno Laboratories has implemented new technology that will allow medical personnel to diagnose Sepsis as much as 24 hours faster. According to the Centers for Disease Control and Prevention, Sepsis, a life-threatening medical emergency, is “the body’s extreme...
A High Sensitivity Cardiac Troponin Assay allows ER doctors to diagnose heart attacks within two hours of a patient’s arrival and may help women as well Heart attacks will be detected faster and more accurately due to a new state-of-the-art, High Sensitivity Cardiac...
Alverno Laboratories is taking the opioid crisis head on with the implementation of groundbreaking, Liquid Chromatography Mass Spectrometer (LCMS) drug testing technology. The state-of-the-art technology, which is being implemented at Hammond, Indiana-based Alverno’s...
Alverno Laboratories’ CEO Sam Terese said his company is at the forefront of the initiative to transform and systemize healthcare as Alverno becomes more of a regional force in the Midwest. Hammond, Indiana-based Alverno Laboratories, which is celebrating its...
